Literature DB >> 12191676

The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes.

Yutaka Aoyagi1, Yuhsaku Mita, Takeshi Suda, Kohichi Kawai, Takashi Kuroiwa, Masato Igarashi, Makoto Kobayashi, Nobuo Waguri, Hitoshi Asakura.   

Abstract

Aim of this study was to establish fucosylation index (FI) of alpha-fetoprotein (AFP) before and after initial treatment as a useful prognostic factor in patients with hepatocellular carcinoma (HCC). One hundred ninety-seven patients with HCC from 1990 to 2000, in whom an increment of serum AFP concentrations more than 30 ng/ml was observed before treatment, were examined in the present study. Enrolled patients with HCC underwent transcatheter arterial embolization, chemoembolization, percutaneous ethanol injection and/or percutaneous microwave coagulation therapy. The current patients status was confirmed as of the end of March 2001. FI was determined by crossed immunoaffinoelectrophoresis in the presence of Lens culinaris agglutinin (LCA). FI of AFP was defined as the percentage of the LCA-reactive species in total AFP (same as L3 fraction). When the tentative discriminating line of FI was set at 18%, the mean survival rate in the HCC group, whose FI-1 (before treatment) was higher than 18% (high FI), was significantly lower than that in another HCC group, whose FI-1 was equal to or less than 18% (low FI) by the generalized Wilcoxon test and the log rank test (P<0.0001). There were statistical significant differences of survival rate when FI-2 (2 months after treatment) and FI-3 (at the time of HCC recurrence or 2 years after treatment in the case of no recurrence) were introduced in the same analysis. Additionally, statistical significant differences of survival rates were obtained between HCC groups with high and low FI-1 when the patient stage was limited to II, III, IVA or IVB. The HCC group, FI-1, FI-2 and FI-3 of which were persistently equal to or less than 18%, showed considerably better prognosis than the group, whose FI-1, FI-2 and FI-3 were persistently higher than 18%. The univariate analysis in the prognostic factor by the Cox's proportional hazards model showed that FI-1, FI-2 and FI-3 were independent prognostic factors. The present study indicates that measuring FI from the sera before and after the treatment serves as a new prognostic indicator and may improve prognostic estimates and appraisal of therapeutic outcome in patients with HCC.

Entities:  

Year:  2002        PMID: 12191676     DOI: 10.1016/s1386-6346(01)00184-x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  13 in total

Review 1.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins.

Authors:  Sudhir Singh; Kuntal Pal; Jessica Yadav; Huiyuan Tang; Katie Partyka; Doron Kletter; Peter Hsueh; Elliot Ensink; Birendra Kc; Galen Hostetter; H Eric Xu; Marshall Bern; David F Smith; Anand S Mehta; Randall Brand; Karsten Melcher; Brian B Haab
Journal:  J Proteome Res       Date:  2015-05-12       Impact factor: 4.466

4.  Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma.

Authors:  Wen-Jiao Zeng; Guo-Yuan Liu; Jie Xu; Xin-Da Zhou; Yue-E Zhang; Nong Zhang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

5.  Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells.

Authors:  Calvin McCarter; Doron Kletter; Huiyuan Tang; Katie Partyka; Yinjiao Ma; Sudhir Singh; Jessica Yadav; Marshall Bern; Brian B Haab
Journal:  Proteomics Clin Appl       Date:  2013-09-13       Impact factor: 3.494

6.  Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations.

Authors:  Yashu Liu; Jintang He; Chen Li; Ricardo Benitez; Sherry Fu; Jorge Marrero; David M Lubman
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

7.  The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays.

Authors:  Tingting Yue; Irwin J Goldstein; Michael A Hollingsworth; Karen Kaul; Randall E Brand; Brian B Haab
Journal:  Mol Cell Proteomics       Date:  2009-04-17       Impact factor: 5.911

8.  The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.

Authors:  Apinya Leerapun; Sri V Suravarapu; John P Bida; Raynell J Clark; Elizabeth L Sanders; Teresa A Mettler; Linda M Stadheim; Ileana Aderca; Catherine D Moser; David M Nagorney; Nicholas F LaRusso; Piet C de Groen; K V Narayanan Menon; Konstantinos N Lazaridis; Gregory J Gores; Michael R Charlton; Rosebud O Roberts; Terry M Therneau; Jerry A Katzmann; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

Review 9.  Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.

Authors:  Danielle L Chappell; Maria C White; Blossom Damania
Journal:  Adv Virus Res       Date:  2020-11-09       Impact factor: 9.937

10.  Glycomic profiling of carcinoembryonic antigen isolated from human tumor tissue.

Authors:  Chuncui Huang; Tiancheng Zhan; Yaming Liu; Qianqian Li; Hongmei Wu; Dengbo Ji; Yan Li
Journal:  Clin Proteomics       Date:  2015-06-27       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.